MD Anderson Research Highlights for February 23, 2022
Â鶹ӳ» MD Anderson Cancer Center¡¯s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current findings include targeted therapies for tumors with PIK3CA and FGFR mutations, a promising combination therapy for myelofibrosis, a new target to improve immunotherapy response in pancreatic cancer, a novel method of increasing...
Newly developed radio-labeled molecule enables real-time imaging of innate immune activity
Researchers at Â鶹ӳ» MD Anderson Cancer Center have developed a new radio-labeled molecule capable of selectively reacting...
MD Anderson receives over $31 million in CPRIT funding
Â鶹ӳ» MD Anderson Cancer Center was awarded $31.73 million from the Cancer Prevention and Research Institute of Texas (CPRIT...
MD Anderson renews partnership with Banner Health
Â鶹ӳ» MD Anderson Cancer Center announced today its first-ever partnership renewal with Banner Health, which created Banner MD Anderson Cancer Center in 2011. The renewed agreement extends the relationship for an additional 10 years.
Banner MD Anderson is a comprehensive and clinically integrated cancer care program and was the first partner to join MD Anderson Cancer Network?, a global network of hospitals and...
MD Anderson Research Highlights for February 9, 2022
Â鶹ӳ» MD Anderson Cancer Center¡¯s Research Highlights provides a glimpse into recently published studies in basic, translational...
MD Anderson honors World Cancer Day, reinforces commitment to cancer care, prevention, research and education
Â鶹ӳ» MD Anderson Cancer Center celebrates World Cancer Day, Feb. 4, in honor of the global initiative to end cancer.
Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma
A study led by researchers at Â鶹ӳ» MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk...